3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

Muscle Nerve · 2018 · PMC5900968 · PMID 29280483

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The 3TUG primary efficacy endpoint demonstrated a highly significant difference between treatment groups in favor of continuous 3,4‐DAP (Table 2 , Fig. 3 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.